Fairvalue-Calculator Fairvalue-Calculator
EN DE

Vectorite Biomedical Inc (4170) Fair Value & Analysis

Healthcare · TW · Market cap 547M TWD

Price12.10 TWD
Fair Value33.22 TWD
Upside+174.5%
Quality95/100
Evidence: Medium Range 24.92 TWD – 55.07 TWD

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Vectorite Biomedical Inc (4170) currently trades at 12.10 TWD, while our model-based Fair Value estimate is 33.22 TWD — implying the stock looks roughly 174.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It is involved in cell preparation product manufacturing; and collection and storage of immune cells. The company's products are used in the field of infectious diseases and inflammation, cancer, oncology. Vectorite Biomedical Inc. was incorporated in 2004 and is based in New Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Vectorite Biomedical Inc (4170) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 33.22 TWD versus a price of 12.10 TWD — about +175% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 4170?
Our 21-model fair value for Vectorite Biomedical Inc is 33.22 TWD (as of Jun 25, 2026), built from audited fundamentals. The current price is 12.10 TWD.
What is the quality score of 4170?
Vectorite Biomedical Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.